fda compounding semaglutide enforcement 2025 news Troubling Findings in Study of GLP-1 Compounders FDA's GLP-1 decision kicks off

Discussion Semaglutide promotes weight loss through appetite suppression and enhanced glucose metabolism

These variants do not predict who will tolerate retatrutide, who will experience side effects, or who will respond to any specific medication, but they can be part of the broader metabolic context informing a provider conversation

The difference was immediate and significant

GLP-1-class drugs amplify this in one indirect way: they work largely by suppressing appetite, which can drive protein intake and overall calories very low if a person simply "isn't hungry." Under-eating protein while losing weight quickly is the single biggest driver of avoidable muscle loss

It works by mimicking a natural hormone called GLP-1 (glucagon-like peptide-1), which regulates appetite and promotes a feeling of fullness

Baseline hormonal status matters as well